Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Graceway Pharmaceuticals, LLC Acquires Worldwide Rights to GS 9191 from Gilead Sciences, Inc. (JOBS)
11/6/2009
-
Gilead Sciences, Inc. to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
11/5/2009
-
Gilead Sciences, Inc. to Present at the Oppenheimer 0th Annual Healthcare Conference on Tuesday, November 3
11/2/2009
-
Gilead Sciences, Inc. Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
11/2/2009
-
Gilead Sciences, Inc. Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) For Chronic Hepatitis B
11/2/2009
-
Gilead Sciences, Inc.'s (JOBS) Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009
10/26/2009
-
Gilead Sciences, Inc. Profit Up 36 Pct, HIV Sales Disappoint
10/21/2009
-
Gilead Sciences, Inc. to Release Third Quarter 2009 Financial Results on Tuesday, October 20, 2009
10/14/2009
-
PARI Pharma's Altera Delivers Gilead Sciences, Inc.'s Cayston, Approved by European Commission to Treat Cystic Fibrosis
9/24/2009
-
Gilead Sciences, Inc.: European Commission Grants Conditional Marketing Authorization to Cayston(R) (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis
9/23/2009
-
Gilead Sciences, Inc. to Present at the UBS Global Life Sciences Conference on Monday, September 21
9/17/2009
-
Gilead Sciences, Inc. to Present at the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9
9/3/2009
-
Gilead Sciences, Inc.'s Executive Vice President Establishes Rule 10b5-1 Stock Trading Plan
8/19/2009
-
Gilead Sciences, Inc. Receives Subpoena from U.S. Department of Health and Human Services Regarding Ranexa(R)
8/17/2009
-
Gilead Sciences, Inc. Announces Colorado Closures; Laying Off At Least 66 People
8/13/2009
-
Gilead Sciences, Inc. Announces Senior Management Promotion of Gregg H. Alton To Vice President, Corporate and Medical Affairs
8/4/2009
-
Kevin E. Lofton Joins Gilead Sciences, Inc.'s Board of Directors
7/30/2009
-
Gilead Sciences, Inc.'s (JOBS) 2nd-Quarter Profit Rises 31 Percent On Sales Of HIV Drugs Atripla, Truvada
7/22/2009
-
Gilead Sciences, Inc. Release: Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
7/21/2009
-
Gilead Sciences, Inc. Announces Agreement With Tibotec Pharmaceuticals Ltd to Develop and Commercialize New Fixed-Dose Combination of Truvada and TMC278
7/17/2009